Contineum Therapeutics (CTNM) Equity Average (2023 - 2025)
Contineum Therapeutics (CTNM) has 3 years of Equity Average data on record, last reported at $175.9 million in Q3 2025.
- For Q3 2025, Equity Average fell 17.74% year-over-year to $175.9 million; the TTM value through Sep 2025 reached $175.9 million, down 17.74%, while the annual FY2024 figure was $65.1 million, N/A changed from the prior year.
- Equity Average reached $175.9 million in Q3 2025 per CTNM's latest filing, down from $178.1 million in the prior quarter.
- Across five years, Equity Average topped out at $213.9 million in Q3 2024 and bottomed at -$76.4 million in Q2 2023.
- Average Equity Average over 3 years is $76.3 million, with a median of $123.4 million recorded in 2024.
- Peak YoY movement for Equity Average: soared 466.91% in 2024, then fell 17.74% in 2025.
- A 3-year view of Equity Average shows it stood at -$64.5 million in 2023, then soared by 416.31% to $204.1 million in 2024, then decreased by 13.82% to $175.9 million in 2025.
- Per Business Quant database, its latest 3 readings for Equity Average were $175.9 million in Q3 2025, $178.1 million in Q2 2025, and $191.4 million in Q1 2025.